Novo Nordisk to Invest Over €400 Million in Athlone Manufacturing Plant Expansion
Tuesday, March 03, 2026
Novo Nordisk has announced an investment of €432 million (approximately DKK 3.2 billion) to expand its manufacturing plant in Monksland, Athlone, Ireland. The site produces tablet-based medicines and the upgrade will increase capacity for current and future GLP-1 treatments.
The investment marks a key strategic step for the company and strengthens its long-term commitment to Ireland. The expansion will enhance manufacturing capabilities for oral products, improve supply, and position Ireland as an important hub for serving markets outside the United States. The project includes upgrading and retrofitting the existing plant to increase production of oral GLP-1 therapies.
The Athlone plant currently employs 260 people, who will continue focusing on delivering high-quality oral treatments in an efficient and environmentally responsible manner. The wider development project, covering 45 acres (18 hectares), is expected to create up to 500 construction jobs.
Construction work has already started and will be completed in stages between late 2027 and 2028.
Source: novonordisk.com
